Learning curve in robotic inguinal hernia repair: a systematic review and meta-analysis.

HerniaSep 16, 2026 (epub)
Clinical ResearchGeneral SurgeryOpen access

Gabriela Lyons, Ana Luiza Aguiar Peres Kozlowski Breves, Vitor Neves et al.

✦ AI-curated · Sources linked

In 30 seconds

This systematic review and meta-analysis evaluated the learning curve in robotic transabdominal preperitoneal (rTAPP) inguinal hernia repair among adult patients. The analysis included 13 studies with 1,770 patients and found a significant reduction in operative time of 17.02 minutes between the initial learning phase and subsequent phases, indicating improved efficiency with experience.

Key findings

  • A pooled reduction in operative time of 17.02 minutes was observed between Phase 1 and Phase 2.
  • The median proficiency threshold for rTAPP was identified as 32 cases.
  • The analysis included 1,770 patients, with 82.8% being male.

Why it matters

Understanding the learning curve in robotic hernia repair is crucial for surgical training and improving patient outcomes. Identifying proficiency thresholds can help guide training programs and enhance surgical efficiency.

Source

PubMed · PMID 42747553Free full text on PubMed Central

Published in Hernia. This summary was written by xxcode from the publication's abstract and metadata. It is not peer reviewed and is not a substitute for the original article. For clinical decisions, review the original publication.

ShareTelegramLinkedIn

AI-generated summaries may contain errors or omissions. Verify clinically important information with the original publication.

More in General Surgery

Clinical ResearchHematology

Ponatinib-Blinatumomab or Imatinib-Chemotherapy for Adult Ph-Positive ALL.

This multicenter, phase 3 randomized trial compared frontline ponatinib plus blinatumomab with imatinib plus chemotherapy in adults with Philadelphia-positive acute lymphoblastic leukemia.

N Engl J MedOct 15, 2026Read summary
Clinical ResearchHematology

Efficacy and safety of mitapivat in patients with sickle cell disease (RISE UP): a phase 3, double-blind, global, randomised, placebo-controlled trial.

RISE UP was a phase 3, double-blind, global, randomised, placebo-controlled trial conducted at 69 sites in 15 countries. It evaluated twice-daily mitapivat in patients older than 16 years with sickle cell disease…

LancetOct 24, 2026Read summary
Clinical ResearchRheumatology

Ianalumab for the Treatment of Patients with Sjögren's Disease.

Two 52-week, double-blind, randomized, placebo-controlled phase III trials evaluated monthly or less frequent ianalumab in patients with active Sjögren's disease.

N Engl J MedOct 22, 2026Read summary

Want this personalized?

Stop searching the literature. Choose what you follow and xxcode will build your personalized medical digest.

  • Your specialties
  • Your filters and thresholds
  • Clinical Research + Case Reports, tuned separately
  • Automatic weekly delivery
  • Audio and text
Create my personalized digestSee plans

Prefer listening? Personalized audio digests are available with Pro.

Stay updated for free

Get the 3 most interesting publications in one specialty each week.

Weekly email. Unsubscribe anytime.